Celcuity Posts Wider FY25 Loss, Highlights Progress Toward Potential Gedatolisib Launch

Celcuity reported fourth-quarter and full-year 2025 financial results and outlined upcoming clinical and regulatory milestones expected to drive the company's development of targeted therapies for solid tumors. The article is a factual release focusing on program timelines and near-term catalysts; no specific financial figures or guidance details were included in the text provided.

Analysis

Celcuity reported fourth-quarter and full-year 2025 financial results and outlined upcoming clinical and regulatory milestones expected to drive the company's development of targeted therapies for solid tumors. The article is a factual release focusing on program timelines and near-term catalysts; no specific financial figures or guidance details were included in the text provided.